Ovarian Cancer Clinical Trial
Official title:
A Phase II Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy
Verified date | March 2020 |
Source | Canadian Cancer Trials Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients with ovarian epithelial cancer, primary peritoneal cancer, and fallopian tube cancer. PURPOSE: This randomized phase II trial is comparing the side effects of three combination chemotherapy regimens and to see how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.
Status | Completed |
Enrollment | 275 |
Est. completion date | July 11, 2016 |
Est. primary completion date | March 10, 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | DISEASE CHARACTERISTICS: - Histologically confirmed ovarian epithelial, primary serous type peritoneal, or fallopian tube carcinoma - Patients with ovarian cancer of the clear cell histology are eligible. Histologic confirmation is preferably by biopsy or limited excision prior to neo-adjuvant treatment. If the diagnosis prior to neo-adjuvant chemotherapy is based on cytology, histologic confirmation is required prior to randomization. Histologic confirmation can be obtained at the time of debulking surgery by intra-operative frozen section, thus permitting intra-operative randomization, or by final pathologic review of the resected specimen if randomization is to be performed following debulking surgery. - Initial FIGO stage IIB-III disease - Stage IV disease allowed provided the only criterion for stage IV disease is the presence of a pleural effusion confirmed to be associated with positive cytology for ovarian cancer - Completed = 3 but no more than 4 courses of platinum-based neoadjuvant chemotherapy prior to the first debulking surgery - Meets the following criteria for surgical treatment prior to randomization: - Initial Diagnosis: No debulking surgery was attempted or completed. - The patient's first cytoreductive (debulking) surgery must be after neoadjuvant chemotherapy (Delayed Primary Debulking). The delayed primary debulking surgery must be completed no more than 4 weeks after commencing administering of the last cycle of neoadjuvant chemotherapy and must be completed no more than 6 weeks prior to randomization. - Surgery will include total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy and any additional procedures required to achieve maximal cytoreduction with residual disease of 1 cm or less as assessed by the surgeon at the end of surgery. - Delayed primary debulking surgery must be completed no more than 4 weeks after the last course of neoadjuvant chemotherapy and must be completed no more than 6 weeks prior to randomization - Surgery will include total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and any additional procedures required to achieve maximal cytoreduction with residual disease of = 1 cm as assessed by the surgeon at the end of surgery - No borderline ovarian tumors (i.e., tumors of low malignant potential) alone - No mucinous tumor PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - Life expectancy = 12 weeks - Granulocyte count = 1.5 x 10^9/L - Platelet count = 100 x 10^9/L - Serum creatinine = upper limit of normal (ULN) OR > ULN to = 1.25 ULN provided measured creatinine clearance is > 60 mL/min - Serum bilirubin normal - AST/ALT = 2.5 times ULN - Fertile patients must use effective contraception - Able (i.e., sufficiently fluent) and willing to complete the quality of life questionnaires - Accessible for treatment and follow-up - No history of other malignancy, except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other solid tumors curatively treated with no evidence of disease for = 5 years - No uncontrolled atrial or ventricular arrhythmias including second or third degree heart block unless managed with implanted pacemaker - Patients with a history of first degree heart block are eligible - No documented myocardial infarction within the past 6 months preceding randomization (pretreatment ECG evidence only of infarct will not exclude patients) - No diagnosis of bowel obstruction - No serious illness or medical condition which would not permit the patient to be managed according to protocol including, but not limited to, any of the following: - Prior allergic reactions to drugs containing cremophor or to compounds chemically related to cisplatin, paclitaxel, or carboplatin - Symptomatic congestive heart failure within the past 6 months or other conditions which would lead to a contraindication of a high-volume saline diuresis - History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent - Active uncontrolled infection - Persistent peripheral neuropathy or hearing loss = grade 2 resulting from prior therapy - Extensive intraperitoneal adhesion intra- or post-operatively which would impede intraperitoneal treatment delivery PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior therapy for ovarian cancer, except for neoadjuvant platinum-based chemotherapy and surgery - No concurrent intraperitoneal adhesion barriers - No other concurrent anticancer treatment, including cytotoxic agents, biological response modifiers, immunotherapy, anticancer hormone therapy, or investigational drug therapy - No other concurrent experimental drugs or anticancer therapy |
Country | Name | City | State |
---|---|---|---|
Canada | Tom Baker Cancer Centre | Calgary | Alberta |
Canada | Cross Cancer Institute | Edmonton | Alberta |
Canada | QEII Health Sciences Centre | Halifax | Nova Scotia |
Canada | BCCA - Cancer Centre for the Southern Interior | Kelowna | British Columbia |
Canada | Cancer Centre of Southeastern Ontario at Kingston | Kingston | Ontario |
Canada | London Regional Cancer Program | London | Ontario |
Canada | CHUM - Hopital Notre-Dame | Montreal | Quebec |
Canada | Hopital Maisonneuve-Rosemont | Montreal | Quebec |
Canada | McGill University - Dept. Oncology | Montreal | Quebec |
Canada | Ottawa Hospital Research Institute | Ottawa | Ontario |
Canada | CHUQ-Pavillon Hotel-Dieu de Quebec | Quebec City | Quebec |
Canada | Regional Health Authority B, Zone 2 | Saint John | New Brunswick |
Canada | Centre hospitalier universitaire de Sherbrooke | Sherbrooke | Quebec |
Canada | Dr. H. Bliss Murphy Cancer Centre | St. John's | Newfoundland and Labrador |
Canada | BCCA - Fraser Valley Cancer Centre | Surrey | British Columbia |
Canada | Thunder Bay Regional Health Science Centre | Thunder Bay | Ontario |
Canada | Univ. Health Network-Princess Margaret Hospital | Toronto | Ontario |
Canada | BCCA - Vancouver Cancer Centre | Vancouver | British Columbia |
Canada | CancerCare Manitoba | Winnipeg | Manitoba |
Spain | Hospital Fundacion Alcorcon | Alcorcon | Madrid |
Spain | Corporacio Sanitaria Clinic | Barcelona | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona | |
Spain | Hospital Vall d'Hebron | Barcelona | |
Spain | Instituto Catalan de Oncologia - L'Hospitalet | Hospitalet de Llobregat | Barcelona |
Spain | Centro Oncologico MD Anderson - Madrid | Madrid | |
Spain | Hospital Clinico San Carlos | Madrid | |
Spain | Hospital Gregorio Maranon | Madrid | |
Spain | Fundacion Instituto Valenciano de Oncologia | Valencia | |
Spain | Hospital Clinico Universitario de Valencia | Valencia | |
United Kingdom | The Western General Hospital - Edinburgh | Edinburgh | |
United Kingdom | St. James University Hospital - Leeds | Leeds | |
United Kingdom | Liverpool Women's Hospital - Liverpool | Liverpool | |
United Kingdom | St. Bartholomew's Hospital - London | London | |
United Kingdom | St. George's Hospital - London | London | Tooting |
United Kingdom | The Hammersmith Hospital - London | London | |
United Kingdom | The Royal Marsden Hospital - London | London | |
United Kingdom | University College London Hospital - London | London | |
United Kingdom | St Marys Hospital - Manchester | Manchester | |
United Kingdom | The Christie Hospital - Manchester | Manchester | Withington |
United Kingdom | Mount Vernon Hospital - Middlesex | Middlesex | Northwood |
United Kingdom | The Churchill Hospital - Oxford | Oxford | |
United Kingdom | The Derriford Hospital - Plymouth | Plymouth | |
United Kingdom | Wexham Park Hospital | Slough | Wexham |
United Kingdom | The Clatterbridge Center for Oncology - Liverpool | Wirral | Bebington |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | Women and Infants Hospital of Rhode Island | Providence | Rhode Island |
United States | Univ of Utah (Huntsman Cancer Institute) | Salt Lake City | Utah |
United States | CoxHealth | Springfield | Missouri |
United States | Mercy-Springfield | Springfield | Missouri |
United States | Northwest CCOP - Multicare Health System | Tacoma | Washington |
Lead Sponsor | Collaborator |
---|---|
Canadian Cancer Trials Group | Cancer Research UK, Grupo Español de Investigación en Cáncer de Ovario, National Cancer Institute (NCI), SWOG Cancer Research Network |
United States, Canada, Spain, United Kingdom,
Provencher DM, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Brundage M, Gourley C, Romero I, Gonzalez-Martin A, Feeney M, Bessette P, Hall M, Weberpals JI, Hall G, Lau SK, Gauthier P, Fung-Kee-Fung M, Eisenhauer EA, Winch C, Tu D, MacKay HJ. OV — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 9-month Progression Rate Post-randomization | It is defined as proportion of patients who had progressed at or before 9 months after randomization, i.e., the time from the randomization to the date when the first observation of disease progression (earliest of the date when the first CA 125 meets progression definition and the date of first objective relapse or progression, defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, recorded) has been documented or when death due to any cause has been observed was less than or equal to 9 months. | 9 months | |
Secondary | Progression Free Survival | Time from the day of randomization until the time when first observation of disease progression (earliest of the dates of first CA125 which meets progression definition and first objective relapse or progression defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, has been documented or when death due to any cause has been observed. | During the study with median follow-up of 33 months | |
Secondary | Overall Survival | Time from the day of randomization to death from any cause. | During the study with median follow-up of 33 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |